tumor prolif fraction solid malign neoplasm compar studi immunostain flow cytometr determin tumor prolif fraction tpf prognosi malign method determin practic accur reproduc compar studi techniqu tpf valu mirror-imag sampl consecut solid malign neoplasm flow cytometri monoclon antibodi unknown nuclear antigen entir cell prolifer cycl cell mean tpf valu case percentag tumor cell rang flow cytometri rang correl strong tumor low s-phase valu equal tumor intermedi high s-phase valu percentag patient age sex tissu origin tumor compar cytometri determin tpf solid malign intermedi high s-phase valu tumor low s-phase valu immunostain tpf valu increas proport cell dilut effect nonneoplast cell tumor low prolif fraction 